Ottobock released financial results of the first nine months of financial year 2025. The company reported revenues of €1,217.8 million (approximately USD $1,409 million) compared to €1,164.5 million for the same period in 2024. Regarding the core business, this translates into revenue growth of 13.6 percent to €1,157.7 million (€1,019.3 million for the same period in 2024). Organic core growth before effects from currency and portfolio changes amounted to 11.5 percent.
The company said that new product launches, positive developments in reimbursement, seven successful acquisitions, as well as strategic investments contributed to the favorable development.
The group underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) increased to €289.6 million. Core business, which encompasses the product categories of products and components and patient care, generated growth of 29.4 percent to EUR 281.1 million.
The underlying core EBITDA margin improved by three percentage points year-on-year to 24.3 percent. In addition to strong growth, the main drivers were a favorable product mix as well as economies of scale and operational efficiency gains, the company said.
Adjusted net income rose by 81.3 percent to €118.7 million. Free cash flow increased by 55 percent.
“We continue on our profitable growth path—the combination of innovative products, targeted acquisitions, and strategic investments in start-ups such as Phantom Neuro, Bionic Skins, or Musclemetrix creates the basis for the next chapter in human-machine interface, said CEO Oliver Jakobi. Our innovative strength remains the key growth driver—the successful IPO now allows us to initiate the next phase of growth
Based on the positive business performance in the first nine months of the year, Ottobock specified its full-year guidance: The core business is expected to grow in the upper half of 10 percent-13 percent (including merger and acquisition activities). Organic core revenue growth is expected between 9 percent-12 percent.
